Black checkmark with a sparkle and a curved line underneath on a white background.
Company

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Ticker
LIXT
Sector
Industry
Report date
November 17, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes various industry updates unrelated directly to LIXTE’s clinical programs or business developments.

Recent developments:
  • No recent direct news on LIXTE’s clinical progress or corporate developments was found in the primary news sources provided [N1][N2][N3][N4][N5][N6][N7][N8].
Overview

LIXTE Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in cancer drug development, focusing on inhibitors of protein phosphatase 2A (PP2A). Its lead compound, LB-100, is undergoing clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and soft tissue sarcoma. LB-100 is designed to enhance the efficacy of chemotherapy, immunotherapy, and radiation therapies without significantly increasing toxicity. The company also holds a majority stake in Liora Technologies Europe Ltd., which develops proton therapy systems. LIXTE operates with minimal overhead and pursues strategic partnerships to advance its clinical programs. Financially, the company reports recurring losses and requires additional capital to sustain operations. In mid-2026, LIXTE was acquired by Nomad Power Solutions, which is focusing on energy infrastructure, with LIXTE’s life-sciences assets considered legacy and under potential disposition.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. LIXTE Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies, primarily the protein phosphatase 2A inhibitor LB-100. The company is conducting multiple clinical trials in collaboration with leading cancer centers. Financial disclosures as of September 30, 2026, show current assets of $17.05 million, current liabilities of $21.82 million, and a net loss of $16.7 million for the nine months ended September 30, 2026. The company faces substantial doubt about its ability to continue as a going concern without additional capital. In June 2026, LIXTE was acquired by Nomad Power Solutions, Inc., which is focusing on transportable power systems and evaluating disposition of LIXTE’s life-sciences portfolio.

Scenarios for LIXT

Bull case model:

The company’s lead compound LB-100 has demonstrated clinical anti-cancer activity and potential to enhance existing cancer therapies without increasing toxicity. Collaborations with reputable cancer centers and pharmaceutical companies support clinical development. The exclusive licensing agreements and patent portfolio provide intellectual property protection. The company’s lean operational model and focus on milestone-driven funding may enable efficient advancement of its pipeline. The acquisition by Nomad Power Solutions could provide additional resources or strategic options for the life-sciences portfolio.

Bear case model:

LIXTE faces significant risks including recurring operating losses, negative cash flows, and substantial doubt about its ability to continue as a going concern without additional capital. Clinical trials have encountered serious adverse events leading to temporary holds, which could delay or terminate development. The company’s life-sciences portfolio is considered legacy under the new parent company, which may lead to divestiture or reduced focus. Market and geopolitical risks, supply chain disruptions, and regulatory uncertainties add to operational challenges. The absence of revenue-generating products limits financial flexibility.

Moat:

LIXTE’s moat lies in its proprietary clinical-stage compound LB-100, which targets protein phosphatase 2A, a novel mechanism in cancer therapy. The company has established intellectual property rights through patents and exclusive licenses with NIH and collaborations with leading cancer research institutions. Its clinical trial collaborations and ongoing research provide a foundation for potential therapeutic differentiation. However, as a clinical-stage biopharmaceutical company without commercial products, its moat is contingent on successful clinical development and regulatory approvals, which remain uncertain.

Risks overview
Risks summary
The most significant risks for LIXTE Biotechnology Holdings, Inc. include its need for additional capital to sustain operations and the potential for clinical trial holds or terminations due to serious adverse events associated with its lead compound LB-100.
Risks details:

• Capital Requirements and Going Concern: The company has recurring losses and negative operating cash flows, with substantial doubt about its ability to continue as a going concern without raising additional capital.
• Clinical Trial Risks and Serious Adverse Events: LB-100 clinical trials have experienced serious adverse events, including patient deaths, leading to temporary holds and increased regulatory scrutiny, which could delay or prevent further development.
• Regulatory and Development Risks: The company’s clinical-stage programs depend on successful regulatory approvals and trial outcomes, which are uncertain and may require additional costly studies.
• Market and Economic Risks: Economic downturns, inflation, and geopolitical uncertainties could adversely affect financing availability, supply chains, and overall business operations.
• Cybersecurity Risks: While the company has policies to manage cybersecurity risks, unauthorized access or incidents could impact information systems and operations.

FINAL FORECAST FOR LIXT

Final take one line
LIXTE Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company with well-documented clinical programs and financial challenges under new ownership focusing on energy solutions.
Final take 12 to 24 month view

Business trends: Continued clinical development of LB-100 in combination with immunotherapy and chemotherapy across multiple cancer indications, alongside potential disposition of life-sciences assets under new ownership.
Execution milestones: Completion of ongoing clinical trials including ovarian clear cell carcinoma and metastatic colon cancer studies; addressing regulatory and safety concerns related to serious adverse events.
Key risks: Need for additional capital to sustain operations; potential clinical trial holds or terminations due to adverse events; uncertainties related to strategic focus shift and asset disposition.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • LIXTE Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton cancer therapy company focused on developing cancer therapies, primarily inhibitors of protein phosphatase 2A (PP2A).
  • The company’s lead clinical compound is LB-100, a small molecule inhibitor of PP2A, which is being tested in clinical trials for ovarian clear cell carcinoma, metastatic microsatellite stable colon cancer, and advanced soft tissue sarcoma.
  • LB-100 has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval in the EU.
  • LB-100 has shown clinical anti-cancer activity and is believed to enhance the effectiveness of chemotherapy, immunotherapy, and radiation without significantly increasing toxicity.
  • The company operates with minimal overhead and raises funds to support clinical milestones, aiming for strategic partnerships or licensing agreements with major pharmaceutical companies.
  • LIXTE is the majority shareholder of Liora Technologies Europe Ltd., which develops electronically controlled proton therapy systems (LiGHT System) for cancer treatment.
  • The company has ongoing clinical collaborations with institutions including the Spanish Sarcoma Group, MD Anderson Cancer Center, Northwestern University, and the Netherlands Cancer Institute.
  • Clinical trials include a Phase 1b/2 trial combining LB-100 with doxorubicin for soft tissue sarcoma, a trial combining LB-100 with GSK’s dostarlimab for ovarian clear cell carcinoma, and a Phase 1b trial combining LB-100 with Roche’s atezolizumab for metastatic colon cancer.
  • The Netherlands Cancer Institute trial was temporarily paused due to two serious adverse events but resumed enrollment after addressing Institutional Review Board concerns.
  • The company has licensed intellectual property rights from NIH related to LB-100 and holds patents covering composition and synthesis of LB-100 and its use in cancer treatment.
  • LIXTE’s financial snapshot as of September 30, 2026, shows current assets of $17.05 million, current liabilities of $21.82 million, cash and equivalents of approximately $3.41 million, a current ratio of 0.78, and a cash ratio of 0.16.
  • The company reported a net loss of $16.7 million for the nine months ended September 30, 2026, and negative operating cash flows, with recurring losses and substantial doubt about its ability to continue as a going concern without additional capital.
  • In June 2026, LIXTE was acquired by Nomad Power Solutions, Inc., which focuses on transportable power and energy storage systems, and LIXTE’s life-sciences portfolio is considered legacy with potential disposition under evaluation.
  • The company’s clinical development programs require substantial expenditures and do not generate sustainable operating revenue currently.
  • Risks include the need for additional capital, potential clinical trial holds or terminations due to serious adverse events, supply chain disruptions, economic downturns, and geopolitical uncertainties.
  • The company has policies to manage cybersecurity risks and has not identified any material cybersecurity incidents affecting operations.
  • Recent news coverage includes various unrelated industry updates; no recent direct news on LIXTE’s clinical progress was found in the primary news sources provided.
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-17 | www.nasdaq.com | Mid-America Apartment Communities, Inc. Details $760.0 Million Active Development Pipeline and Financial Outlook | https://www.nasdaq.com/articles/mid-america-apartment-communities-inc-details-7600-million-active-development-pipeline-and
  • N2 | 2026-11-17 | www.nasdaq.com | Seanergy Maritime Holdings Corp. Reports Record Nine-Month Net Income of $61.9 Million and Raises Quarterly Dividend to $0.40 Per Share | https://www.nasdaq.com/articles/seanergy-maritime-holdings-corp-reports-record-nine-month-net-income-619-million-and
  • N3 | 2026-11-17 | www.nasdaq.com | Cumberland Pharmaceuticals Inc. Announces Plans to File New Drug Application for Ifetroban DMD Program | https://www.nasdaq.com/articles/cumberland-pharmaceuticals-inc-announces-plans-file-new-drug-application-ifetroban-dmd
  • N4 | 2026-11-17 | www.nasdaq.com | Aqua Metals, Inc. Reports Third Quarter 2026 Financial Results and Establishes Offtake Pathways | https://www.nasdaq.com/articles/aqua-metals-inc-reports-third-quarter-2026-financial-results-and-establishes-offtake
  • N5 | 2026-11-17 | www.nasdaq.com | Brainstorm Cell Therapeutics Inc. Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/brainstorm-cell-therapeutics-inc-reports-third-quarter-2026-financial-results
  • N6 | 2026-11-17 | www.nasdaq.com | FB Financial Corporation Details Q3 2026 Financial Position and Capital Activities in Fourth Quarter Investor Presentation | https://www.nasdaq.com/articles/fb-financial-corporation-details-q3-2026-financial-position-and-capital-activities-fourth
  • N7 | 2026-11-17 | www.nasdaq.com | Priveterra Acquisition Corp. II Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/priveterra-acquisition-corp-ii-reports-third-quarter-2026-financial-results
  • N8 | 2026-11-17 | www.nasdaq.com | Mastercard Introduces Mastercard Accept To Enable Debit And Prepaid Cardholders To Receive Payments | https://www.nasdaq.com/articles/mastercard-introduces-mastercard-accept-enable-debit-and-prepaid-cardholders-receive
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine